CliffBio
biologic

Rebinyn

Coagulation Factor IX (Recombinant), GlycoPEGylated

Loss of exclusivityAugust 2034projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameRebinyn
Active ingredientCoagulation Factor IX (Recombinant), GlycoPEGylated
Strength3000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2022
Marketing statusRx

More from Novo Nordisk Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Rebinyn patent cliff — loss of exclusivity August 2034 | CliffBio